medigraphic.com

2003, Number s1

<< Back Next >>

Arch Cardiol Mex 2003; 73 (s1)

Inflammation in atherosclerosis

Trevethan CS

Language: Spanish
References: 16
Page: 141-145
PDF size: 64.39 Kb.


ABSTRACT

Traditional risk factors for atherosclerosis are well known and their control decreases importantly the appearance of the disease. These factors are the genetic charge, dyslipidemia, smoking, systemic arterial hypertension, diabetes, obesity, gender, age, stress, estrogen levels in women, and life style. However, in the last decade, new risk factors have been identified especially for coronary and cerebrovascular atherosclerosis. Among these factors, the inflammatory process has been pointed out in which acute stage reactants participate, such as C-reactive protein, leukocyte count, globular sedimentation, multiple cytokines, alpha tumor necrosis factor, vascular and cellular adhesion molecules, some metalloproteinases, pregnancy-associated plasma protein A, lipoprotein-associated phospholipase A2, angiotensin II, and very probably infection. This article discusses the mechanism by which these markers participate in the atherosclerotic process and their value as predictors of future coronary events, as well as to what extent current therapeutics can contribute to decrease these events and to improve patient care.


REFERENCES

  1. Ross R: Atherosclerosis an-inflammatory disease. N Engl J Med 1999; 340: 115-26.

  2. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB: Fibrinogen and risk of cardiovascular disease: The Framingham Stud. JAMA 1987; 258: 1183-6.

  3. Packard CJ, O’Reilly DS, Caslake MJ, Mc Mahon AD, Ford I, Cooney I, et al: Lipoprotein-associate phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148-55.

  4. Stafforini DM, McIntyre TM, Zimmerman GA, Prescot SM: Platelet activating factor acetylhydrolases. J Biol Chem 1997; 272: 17895-8.

  5. Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kübler W: Angiotensin Induces Inflammatory Activation of Human Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-29.

  6. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, et al: Pregnancy-Associated Plasma Protein a as a Marker of Acute Coronary Syndromes. N Engl J Med 2001; 345: 1022-9.

  7. Lusis AJ: Atherosclerosis. Nature 2000; 407234-9.

  8. Ridker PM, Hennekens CH, Buring JE, Rifai NC: Reactive Protein and other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. New Engl J Med 2000; 342: 836-43.

  9. Koening W, Sund M, Frölich M, Fischer HG, Löwel H, Döring A, et al: C-Reactive Protein, a Sensitive Marker of Inflammation,Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Age Men. Results From the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausgsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.

  10. ISIS-2 (second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute miocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.

  11. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healtly men. N Engl J Med 1997; 336: 973-9.

  12. Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD 11 b expression and CD 11 B-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7.

  13. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 427-31.

  14. Ridker MP, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurret Events (CARE) Investigators. Circulation 1999; 100: 230-5.

  15. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, López R, et al: Efficacy Assessment of Meloxicam, a Preferential Cyclooxigenase-2 Inhibitor, in acute Coronary Syndromes Without ST-Segment Elevation. The Nonsteroidal Anti-Inflamatory Drugs in Unestable Angina treatment-2 (NUT-2) pilot Study. Circulation 2002; 106: 191-5.

  16. Pearson TA, Mensah GA, Wayne Alexander R, Anderson JL, Cannon RO, Criqui M, et al: Markers of Inflammation and Cardiovascular Disease. Circulation 2003; 107: 499.




2020     |     www.medigraphic.com